Use of fructose-1 6-diphosphate as an inotrope drug after cardiopulmonary bypass surgery
US5944020A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 3, 1997 |
| Grant date | Aug 31, 1999 |
| Priority date | — |
| Expiry date | Oct 3, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61B2017/00243
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
When fructose-1,6-diphosphate (FDP) is used as an inotropic drug in patients who have undergone surgery involving cardiopulmonary bypass, it can increase the pumping strength of a struggling heart, without increasing the heartbeat rate. As such, FDP can reduce the dosages of (and in some some cases eliminate the need for) other inotropic drugs such as dobutamine, epinephrin, or amrinone lactate, which have undesired and potentially dangerous side effects, mainly involving increasing the heartbeat rate, which imposes substantial additional stresses on hearts that are struggling to regain strength after cardiopulmonary bypass surgery.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.